Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.

In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) initiating secukinumab, we aimed to assess and compare the proportion of patients achieving 6-, 12- and 24-month patient-reported outcomes (PRO) remission and the 24-month retention rates. Patients with axSpA or PsA from 16 European registries, who initiated secukinumab in routine care were included. PRO remission rates were defined as pain, fatigue, Patient Global Assessment (PGA) ≤2 (Numeric Rating Scale (NRS) 0-10) and Health Assessment Questionnaire (HAQ) ≤0.5, for both axSpA and PsA, and were calculated as crude values and adjusted for drug adherence (LUNDEX). Comparisons of axSpA and PsA remission rates were performed using logistic regression analyses (unadjusted and adjusted for multiple confounders). Kaplan-Meier plots with log-rank test and Cox regression analyses were conducted to assess and compare secukinumab retention rates. We included 3087 axSpA and 3246 PsA patients initiating secukinumab. Crude pain, fatigue, PGA and HAQ remission rates were higher in axSpA than in PsA patients, whereas LUNDEX-adjusted remission rates were similar. No differences were found between the patient groups after adjustment for confounders. The 24-month retention rates were similar in axSpA vs. PsA in fully adjusted analyses (HR [95 %CI] = 0.92 [0.84-1.02]). In this large European real-world study of axSpA and PsA patients treated with secukinumab, we demonstrate for the first time a comparable effectiveness in PRO remission and treatment retention rates between these two conditions when adjusted for confounders.

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Sara Nysom Christiansen, Simon Horskjær Rasmussen, Lykke Midtbøll Ørnbjerg: research grant from Novartis; Marion Pons: research grant from Novartis and speaker fees from Sandoz; Brigitte Michelsen: research grant from Novartis and the centre for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY) is funded as a Centre for Clinical Treatment Research by The Research Council of Norway (project 328,657); Bente Glintborg: research grants from Pfizer, Abbvie, BMS, Sandoz; Bjorn Gudbjornsson: consulting fees from Novartis and speaker fees from Novartis, Nordic-Pharma; Gerdur Grondal: none; Jiri Vencovsky: research grant from Abbvie, consulting fees from Abbvie, Argenx, Boehringer, Eli Lilly, Gilead, Octapharma, Pfizer, UCB and speaker fees from Abbvie, Biogen, Boehringer, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi, UCB, Werfen; Anne Gitte Loft: research grant from Novartis andspeaking and/or consulting fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, UCB, paid instructor from Pfizer; Ziga Rotar: consulting fees from Abbvie, Novartis, Eli Lilly, Pfizer, Janssen and speaker fees from Abbvie, Amgen, Novartis, MSD, Medis, Biogen, Eli Lilly, Pfizer, Sanofi, Lek, Janssen; Katja Perdan Pirkmajer: consulting fees from Abbvie, Novartis, Medis, Eli Lilly, Pfizer, Boehringer Ingelheim and speaker fees from Abbvie, Novartis, MSD, Medis, Eli Lilly, Pfizer, Lek, Janssen; Michael J. Nissen: research grant from Pfizer andconsulting and/or speaker fees from Abbvie, Eli Lilly, Janssens, Novartis, Pfizer; Jana Baranova: none; Gary J. Macfarlane: research grant from GSK; Gareth T.Jones: research grants from Abbvie, Pfizer, UCB, Amgen, GSK and speaker fees from Janssen; Florenzo Iannone: research grant from BMS, Galapagos, Pfizer and consulting and/or speakers fees from Abbvie, Amgen, AstraZeneca, BMS, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, UCB; Roberto Caporali: consulting and/or speaker fees from Abbvie, Amgen, AstraZeneca, BMS, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, UCB; Karin Laas: research grant from Abbvie, Johnson and Johnson, Novartis, Pfizer; Sigrid Vorobjov: none; Daniella Di Giuseppe: none; Tor Olofsson: none; Sella Aarrestad Provan: Research grant from Boehringer Ingelheim and consulting fees from Boehringer Ingelheim; Karen Minde Fagerli: none; Isabel Castrejon: consulting and speaker fees from BMS, Eli-Lilly, Galapagos, Gilead, Janssen, Novartis, MSD, Pfizer, GSK; Lucia Otero-Varela: None; Marleen Van de Sande: research grants from UCB, Janssen, Novartis, Eli Lilly, consulting fees from Novartis, Abbvie, Eli Lilly UCB and speaker fees from Novartis, UCB, Janssen; Irene van der Horst-Bruinsma: Unrestricted Grants received for investigator initiated studies from MSD, Pfizer, AbbVie, UCB. Fees received for lectures from BMS, AbbVie, Pfizer, MSD, UCB, consulting fees from Abbvie, UCB, MSD, Novartis, Lilly and speaker fees from UCB; Dan Nordström: research grant from MSD, consulting fees from Abbvie, BMS, Lilly, MSD, Novartis, Pfizer, Roche, UCB, and speaker fees from Novartis, Pfizer, UCB; Laura Kuusalo: consulting fees from Gilead, Pfizer and speaker fees from Abbvie, Lilly, Medac, Orion, Pfizer, UCB; Miguel Bernades: none; Merete Lund Hetland: Research grants from Novartis, Abbvie, Biogen, BMS, Celltrion, Eli Lilly, Janssen Biologics B.V, Lundbeck Fonden, MSD, Medac, Pfizer, Roche, Samsung Biopies, Sandoz, Novartis, Nordforsk, consulting fees from Abbvie, chaired the steering committee of the Danish Rheumatology Quality Registry (DANBIO, DRQ), which receives public funding from the hospital owners and funding from pharmaceutical companies and speaker fees from Pfizer, Medac, Sandoz; Mikkel Østergaard: Research grant from Abbvie, BMS, Merck, Novartis and UCB and consulting and/or speaker fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi, UCB